fda glp-1 compounding enforcement november 2025 Safe use of compounded GLP products FDA Moves to Restrict Mass-Marketed

Oct 2018;50:152-165

GPX4 and glutaminase inhibitors can inhibit pyrimidine synthesis and increase ROS levels in VHL-deficient renal carcinoma cells, and the PARP inhibitor olaparib and glutaminase inhibitors can synergistically inhibit the growth of these cells in vivo and in vitro

No rigid rules

doi: 10.1111/cen.13474

1 2 Journal of Clinical Densitometry (Review)

Lower-cost versions can drive volume growth in high-need markets, but faster-than-expected price erosion across multiple countries could reduce the categorys overall revenue potential and raise the bar for next-generation obesity drugs to justify premium pricing